ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Staff Advisory Boards To Be Formed; Three BSCs Proposed

August 11, 1995

Ivax Paclitaxel To Remain On Market In Deal With BMS.

February 1, 2002

RFP: Sole Source

May 12, 2000

Final Issue Of the Year

December 14, 1990

Clinical Trials Approved Last Month By NCI’s CTEP

May 31, 2002

In Brief: Potter New AACI President, Sartorlli President Elect; NCI Staffers Get NIH Director’s Award

July 18, 1986